JAMA Network Open
EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, OCTOBER 15, 2020
Media advisory: The full study and commentary are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2020.20977?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101520
About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
What The Study Did: Testimonials posted on a social media site were analyzed to examine whether individuals are using the cannabis-derived chemical compound cannabidiol (CBD) in an attempt to treat diagnosable conditions that have evidence-based therapies.
Authors: John W. Ayers, Ph.D., M.A., of the University of California, San Diego, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.